Skip to main content
Premium Trial:

Request an Annual Quote

IP Watch: Roche, Sysmex, Eppendorf, Gen-Probe, and Others Win US Patents

Premium

Roche has been awarded US Patent Nos. 8,198,422 and 8,198,423, both entitled "High-risk human papillomavirus detection."

Janet Kornegay, Carrie Aldrich, and Stephen Will are named as inventors on the patents.

The patents provide compositions, methods, related kits, systems, and computers for detecting HPV in a sample.


Sysmex has been awarded US Patent No. 8,198,052, "Primers for nucleic acid amplification in detecting β-actin and test method using these primers."

Sachiyo Tada is named as inventor on the patent.

Provides novel primers for nucleic acid amplification to be used in detecting mRNA of a housekeeping gene, and more particularly for confirming the amplification of β-actin or GAPDH. More specifically, primers containing oligonucleotides having specific nucleotide sequences described in detail in the patent can be selected, combined, and used.


Eppendorf has been awarded US Patent No. 8,198,051, "Thermocycler with a temperature control block driven in cycles."

Kirsten Schicke and Claudia Hofmann are named as inventors on the patent.

Describes a thermocycler comprising a temperature control block that is designed to receive several specimens and is fitted with a control unit that in consecutive cycles applies the different temperature levels (40° C., 70° C, 95° C) of a PCR procedure to said block. The temperature-controlling block is subdivided into thermally separate segments, each of which is controlled separately and receives several specimens, the control unit being designed to drive the said segments at different cycling rates, according to the patent's abstract.


Gen-Probe has been awarded US Patent No. 8,198,027, "Methods and compositions for nucleic acid amplification."

Steven Brentano, Dmitry Lyakhov, James Carlson, Norman Nelson, and Lyle Arnold are named as inventors on the patent.

Discloses compositions that are used in nucleic acid amplification in vitro. The compositions include a target-specific universal (TSU) "promoter-primer" or "promoter-provider" oligonucleotide that includes a target-specific sequence that hybridizes specifically to a target sequence that is amplified. The compositions also include a universal sequence that is introduced into the sequence that is amplified, by using a primer for the universal sequence. The patent discloses methods of in vitro nucleic acid amplification that use one or more TSU oligonucleotides to attach a universal sequence to a target nucleic acid in a target-capture step; and then use a primer for a universal sequence in subsequent amplification steps performed in substantially isothermal conditions to make amplification products that contain a universal sequence indicating the presence of the target nucleic acid in a sample.


Institut Biokhimii I Genetiki Ufimskogo Nauchnogo Tsentra Ran, in Moscow, has been awarded US Patent No. 8,198,026, "Method of detecting specific fragments of DNA or RNA with the aid of a real-time polymerase chain reaction."

Alexei Chemeris, Yury Nikonorov, Maiya Leonidovna, Dmitry Chemeris, Ravil Garafutdinov, Roza Magazova, Grigory Maleev, Vener Vakhitov, and Raif Vasilov are named as inventors on the patent.

Discloses methods of amplifying specific fragments of DNA or RNA with the aid of a real-time PCR. The methods include providing a first oligonucleotide primer that comprises a donor fluorescent dye and a second oligonucleotide primer that comprises an acceptor fluorescent dye; allowing the primers to anneal to a target nucleic acid at positions abutting each other or overlapping; carrying out a PCR that allows for a fluorescent resonance transfer of energy between the donor dye and the acceptor dye; detecting an increase of fluorescent emission of the acceptor dye; and correlating the increase in the emission of the acceptor dye with the accumulation of the specific fragment of DNA or RNA. In one embodiment, the primers comprise a fluorescent dye and a universal quencher.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.